San Ysidro Health Running DRES-POCAI RCT — 848 Patients, EyeArt Point-of-Care AI for Diabetic Retinopathy at CA FQHC
San Ysidro Health (San Diego CA FQHC) is running the most rigorous CA FQHC-based AI diabetic retinopathy trial currently underway. DRES-POCAI (Diabetic Retinopathy Screening with Point-of-Care AI) RCT: 848 patients across 2 FQHC sites, EyeArt-based point-of-care AI integrated with EHR. Primary outcome: DR screening completion at 90 days. Funded by Gordon and Betty Moore Foundation + Kaiser Permanente AIM-HI. ClinicalTrials.gov NCT06721351. Trial protocol published in JAMA Network Open. This positions San Ysidro Health as a national leader in FQHC AI vision deployment. Outcomes will inform NACHC/AOA/CHCF policy recommendations on autonomous AI DR screening reimbursement and FQHC capital deployment priorities.
Primary source
JAMA Network OpenAffected FQHCs
FQHC Talent. (2026, January 15). San Ysidro Health Running DRES-POCAI RCT — 848 Patients, EyeArt Point-of-Care AI for Diabetic Retinopathy at CA FQHC. Primary source: JAMA Network Open. Retrieved May 1, 2026, from https://www.fqhctalent.com/intel/san-ysidro-health-dres-pocai-rct-2026
More in Strategy & Tactics
Apr 30
Epic's 2026 AI Rollout (Art, Emmie, Penny) Reaches OCHIN — But on a 6-18 Month Lag
Apr 30
Abridge Names FQHC Cohort: AltaMed, El Rio, Yakima Valley Farm Workers, TrueCare
Apr 17
CHCF Brief: Assisted Living as Housing Solution for Californians with Behavioral Health Needs
Apr 15
Ophthalmology Science Names FQHCs as 'Ideal Locations' for Autonomous AI Diabetic Retinopathy Screening — Real-World Adoption Playbook